Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 19, 2018

View Archived Issues

Moleculin Biotech and MD Anderson discover new STAT3 inhibitor

Japanese approval for Actair for children with house dust mite-induced allergic rhinitis

Novoheart and Sumocor enter agreement to develop therapeutics for heart failure

RCGD-423 prevents articular cartilage degeneration and promotes repair in vivo

FDA grants orphan drug designation to ProMetic's IaIp for necrotizing enterocolitis

Novel Toll-like receptor 2 antagonists discovered at Neuropore Therapies

FDA issues complete response letter for Vitaros

Bayer patents new menin/MLL interaction inhibitors

IOCB Prague and Palecky University Olomouc describe new anticancer nucleosides

Dosing begins in phase Ib study of MYK-491

Bristol-Myers Squibb identifies novel Toll-like receptor 7/8/9 antagonists

New NMDA NR2 receptor modulators synthesized at Aptinyx

CSIC, Centre Hospitalier Universitaire Vaudois present novel compounds for pancreatic cancer

Gilead Sciences' Harvoni approved for new indication in Japan

Phase I results for VRC-5288 and VRC-5283 Zika virus DNA vaccine candidates

Avillion opens IND for phase II study of Merck KGaA's M-1095

Wilson Therapeutics initiates phase III trial of WTX-101 for Wilson's disease

FDA approves Imfinzi for unresectable stage III NSCLC

Palbociclib shows limited activity in metastatic urothelial cancer trial

Sumitomo Dainippon Pharma, Intercept amend obeticholic acid agreement

Shire presents clinical data on SHP-647 for the treatment of Crohn's disease

Rapid remission seen in Crohn's disease patients treated with upadacitinib

Fluarix Tetra approved in Europe for use from 6 months of age

FDA grants orphan drug designation to Hansa's IdeS for Guillain-Barre syndrome

Galderma signs joint research agreement on atopic dermatitis with Icahn and Northwestern University

Cincera Therapeutics launches with aim of treating diseases associated with obesity

Great Point Partners expresses opposition to BioCryst's proposed merger with Idera

TRDN user survey - We want your opinion

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026